Floatz logo

DARATUMUMAB

Plasmacytoma

Seoul National University Hospitalmonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Plasmacytoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 2B
Cediranib
M.D. Anderson Cancer Center
Phase 2B
cc-5013
Memorial Sloan Kettering Cancer Center
Phase 2B
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2B
Fludarabine
M.D. Anderson Cancer Center
Phase 2B

View all 19 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →